217 related articles for article (PubMed ID: 29750408)
1. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
2. Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelch-like ECH-Associated Protein 1 (KEAP1) and Nuclear Factor Erythroid 2 Like 2 (Nrf2).
Zhong M; Lynch A; Muellers SN; Jehle S; Luo L; Hall DR; Iwase R; Carolan JP; Egbert M; Wakefield A; Streu K; Harvey CM; Ortet PC; Kozakov D; Vajda S; Allen KN; Whitty A
Biochemistry; 2020 Feb; 59(4):563-581. PubMed ID: 31851823
[TBL] [Abstract][Full Text] [Related]
3. Advances in developing noncovalent small molecules targeting Keap1.
Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of Keap1-Nrf2 protein-protein interaction reduce estrogen responsive gene expression and oxidative stress in estrogen receptor-positive breast cancer.
Xie T; Zahid H; Ali AR; Joyce R; Yang G; Winz C; Le Y; Zhou R; Furmanski P; Hu L; Suh N
Toxicol Appl Pharmacol; 2023 Feb; 460():116375. PubMed ID: 36634873
[TBL] [Abstract][Full Text] [Related]
5. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
6. Screening approaches for the identification of Nrf2-Keap1 protein-protein interaction inhibitors targeting hot spot residues.
Asano W; Hantani R; Uhara T; Debaene F; Nomura A; Yamaguchi K; Adachi T; Otake K; Harada K; Hantani Y
SLAS Discov; 2024 Mar; 29(2):100125. PubMed ID: 37935317
[TBL] [Abstract][Full Text] [Related]
7. Beyond repression of Nrf2: An update on Keap1.
Kopacz A; Kloska D; Forman HJ; Jozkowicz A; Grochot-Przeczek A
Free Radic Biol Med; 2020 Sep; 157():63-74. PubMed ID: 32234331
[TBL] [Abstract][Full Text] [Related]
8. Small Molecule Compounds That Inhibit Antioxidant Response Gene Expression in an Inducer-Dependent Manner.
Edwards MR; Liu G; De S; Sourimant J; Pietzsch C; Johnson B; Amarasinghe GK; Leung DW; Bukreyev A; Plemper RK; Aron Z; Bowlin TL; Moir DT; Basler CF
ACS Infect Dis; 2020 Mar; 6(3):489-502. PubMed ID: 31899866
[TBL] [Abstract][Full Text] [Related]
9. Structural modification of C2-substituents on 1,4-bis(arylsulfonamido)benzene or naphthalene-N,N'-diacetic acid derivatives as potent inhibitors of the Keap1-Nrf2 protein-protein interaction.
Lee S; Ali AR; Abed DA; Nguyen MU; Verzi MP; Hu L
Eur J Med Chem; 2024 Feb; 265():116104. PubMed ID: 38159482
[TBL] [Abstract][Full Text] [Related]
10. The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer.
Xia L; Ma W; Afrashteh A; Sajadi MA; Fakheri H; Valilo M
Biochem Med (Zagreb); 2023 Oct; 33(3):030504. PubMed ID: 37841775
[TBL] [Abstract][Full Text] [Related]
11. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
[TBL] [Abstract][Full Text] [Related]
12. A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants.
Aboulkassim T; Tian X; Liu Q; Qiu D; Hancock M; Wu JH; Batist G
Cell Rep; 2023 Sep; 42(9):113104. PubMed ID: 37703174
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of NRF2 is correlated with the magnitude of inflammation and fibrosis in chronic liver disease.
To K; Okada K; Watahiki T; Suzuki H; Tsuchiya K; Tokushige K; Yamamoto M; Ariizumi SI; Shoda J
Cancer Med; 2023 Oct; 12(19):19423-19437. PubMed ID: 37732511
[TBL] [Abstract][Full Text] [Related]
14. S-lactoyl modification of KEAP1 by a reactive glycolytic metabolite activates NRF2 signaling.
Ko Y; Hong M; Lee S; Kumar M; Ibrahim L; Nutsch K; Stanton C; Sondermann P; Sandoval B; Bulos ML; Iaconelli J; Chatterjee AK; Wiseman RL; Schultz PG; Bollong MJ
Proc Natl Acad Sci U S A; 2023 May; 120(20):e2300763120. PubMed ID: 37155889
[TBL] [Abstract][Full Text] [Related]
15. The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding.
Gacesa R; Lawrence KP; Georgakopoulos ND; Yabe K; Dunlap WC; Barlow DJ; Wells G; Young AR; Long PF
Biochimie; 2018 Nov; 154():35-44. PubMed ID: 30071261
[TBL] [Abstract][Full Text] [Related]
16. Cyclic Peptide Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury.
Zou J; Yan J; Lu Y; Yu Z; Zhang K; Han Q; Han D; Gai C; Chai X; Zhao Q; Zhuang C; Zou Y
J Med Chem; 2024 Mar; 67(6):4889-4903. PubMed ID: 38485922
[TBL] [Abstract][Full Text] [Related]
17. Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors.
Otake K; Hara Y; Ubukata M; Inoue M; Nagahashi N; Motoda D; Ogawa N; Hantani Y; Hantani R; Adachi T; Nomura A; Yamaguchi K; Maekawa M; Mamada H; Motomura T; Sato M; Harada K
J Med Chem; 2024 Mar; 67(5):3741-3763. PubMed ID: 38408347
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting the Keap1/Nrf2 Protein-Protein Interaction with Protein-Like Polymers.
Carrow KP; Hamilton HL; Hopps MP; Li Y; Qiao B; Payne NC; Thompson MP; Zhang X; Magassa A; Fattah M; Agarwal S; Vincent MP; Buyanova M; Bertin PA; Mazitschek R; Olvera de la Cruz M; Johnson DA; Johnson JA; Gianneschi NC
Adv Mater; 2024 Jan; ():e2311467. PubMed ID: 38241649
[TBL] [Abstract][Full Text] [Related]
19. Computational Prediction of Cyclic Peptide Structural Ensembles and Application to the Design of Keap1 Binders.
Fonseca Lopez F; Miao J; Damjanovic J; Bischof L; Braun MB; Ling Y; Hartmann MD; Lin YS; Kritzer JA
J Chem Inf Model; 2023 Nov; 63(21):6925-6937. PubMed ID: 37917529
[TBL] [Abstract][Full Text] [Related]
20. Small molecule deoxynyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapy.
Linghu KG; Zhang T; Zhang GT; Lv P; Zhang WJ; Zhao GD; Xiong SH; Ma QS; Zhao MM; Chen M; Hu YJ; Zhang CS; Yu H
J Pharm Anal; 2024 Mar; 14(3):401-415. PubMed ID: 38618249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
